Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 11, 2016 10:45 AM ET

Company Overview of Skåne University Hospital

Company Overview

Lund University Hospital Sweden is an educational institution.



Key Executives for Skåne University Hospital

Skåne University Hospital does not have any Key Executives recorded.

Skåne University Hospital Key Developments

NeuroVive Pharmaceutical AB and Skåne University Hospital Initiate Collaboration on Clinical Phase II Study on Kidney Protection During Heart Surgery

NeuroVive Pharmaceutical AB has initiated a collaboration with Skåne University Hospital to complete a clinical phase II study on the evaluation of the company's product CicloMulsion(R) regarding its ability to prevent acute kidney injury in 150 patients undergoing heart surgery. Enrolment to the study will begin in the first half of 2015 and is expected to continue until the end of 2016. NeuroVive's product CicloMulsion(R) is already being evaluated in clinical studies focusing on protecting the heart and brain in connection with acute injury (known as NeuroSTAT(R) for brain protection). Drugs that protect the mitochondria also have significant potential to protect high-energy organs like the kidneys during surgery. Two clinical studies have shown that the active substance is safe for heart surgery and provides protection against diffuse injury*. This has led Skåne University Hospital to initiate a clinical study to evaluate the potential for protecting the kidneys using CicloMulsion(R) in cardiac surgery. The study is known as CiPRICS (Ciclosporin to Protect Renal function In Cardiac Surgery) and is a double-blind, randomized and placebo-controlled clinical phase II study to include a total of 150 patients. The patients will be treated with CicloMulsion(R) in connection with coronary artery bypass surgery at the Clinic for Cardiothoracic Surgery at Skåne University Hospital in Lund, Sweden. The study is investigator-initiated and is conducted with support from NeuroVive.

Similar Private Companies By Industry

Company Name Region
Officersförbundet Europe
Sulzer Pump Solutions Sweden AB Europe
Knut Hansson Holding AB Europe
Narvestad Invest AB Europe
Indevo AB Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Skåne University Hospital, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at